“The existing condition has exposed some structural weaknesses while in the EU’s medicines supply chain along with a substantial dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides said. She suggested that provide chain concerns be dealt with in an EU pharmaceutical system expected to get introduced by the end https://www.rilife.co/advanced-pharmaceutical-ingredients-importers-exporter-suppliers-in-india-2/